

1 **Supporting Information**

2 **Phospho-proteome Analysis of Cerebrospinal Fluid Extracellular Vesicles in**

3 **Primary Central Nervous System Lymphoma**

4 Yuanyuan Deng,^a Qing Li,^b Jie Sun,^a Leyao Ma,^a Yajie Ding,^a Yuhan Cai,^a Anton

5 Iliuk,^c Bobin Chen,^b Zhuoying Xie,^{*a} and W. Andy Tao ^{*a,c,d,e}

6 ^a State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical

7 Engineering Education, Southeast University, Nanjing, China.

8 ^b Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China.

9 ^c Department of Biochemistry, Purdue University, West Lafayette, IN 47907.

10 ^d Department of Chemistry, Purdue University, West Lafayette, IN 47907.

11 ^e Center for Cancer Research, Purdue University, West Lafayette, IN47907.

12

13

14 **Table of Contents**

15 Supporting Experimental Section. (PDF)

16 **Figure S1.** Gene Ontology (GO) analysis of LC-MS proteome data from EV samples

17 captured by EVtrap. (PDF)

18 **Figure S2.** Repeatability among biological replicates of phosphoproteome analysis.

19 (PDF)

20 **Figure S3.** Number of identified peptides and proteins in CSF EV from PCNSL group

21 and non-PCNSL control, and repeatability among biological replicates of proteome

22 analysis. (PDF)

23 **Table S1.** LC-MS proteome analysis data for EVTRAP and UC comparison. (Table

24 S1)

25 **Table S2.** Information of pooled samples. (PDF)

26 **Table S3.** EVTRAP-based proteome data in PCNSL. (Table S2)

27 **Table S4.** EVTRAP-based phosphoproteome data in PCNSL. (Table S3)

28 **Table S5.** Label-free quantification analysis results. (Table S4)

29 **Supporting Experimental Section**

30 **Ultracentrifugation for EV Isolation**

31 The frozen CSF were thawed in 37°C water bath and centrifuged for 10 min at 2500 g
32 firstly at room temperature. The collected supernatant was then diluted two-fold with
33 pre-cooled PBS (4°C) and centrifuged at 20,000 g for 1 hr. Afterward, the supernatant
34 was centrifuged at 100,000 g for 70 min at 4°C. After removal of supernatant, the pre-
35 cooled PBS was added to resuspend the pellet and samples were centrifuged again for
36 70 min at 100,000 g. Finally, the washed EV pellet was collected for further experiment.

37 **TEM Imaging and NTA**

38 EV solution of 10 μL was dropped onto 200-mesh formvar carbon-coated copper grids
39 and incubated with the negatively stained solution (2% phosphotungstic acid solution,
40 pH = 7.0) at room temperature for 2–3 min. Finally, transmission electron microscopy
41 (TEM) imaging was carried out on a JEOL JEM-2100 electron microscope (JEOL,
42 Tokyo, Japan) with an accelerating applied potential of 200kV.

43 EVs isolated from 0.5 mL CSF sample were eluted twice with 100 μL of 100 mM TEA
44 and diluted five-fold with PBS. Then, the EV solution was used for nanoparticle
45 tracking analysis (NTA) on a ZetaView (Particle Metrix, Meerbusch, Germany) after
46 calibration with 100 nm polystyrene particles.

47 **Western Blotting Analysis**

48 Purified EV samples were first boiled in LDS loading buffer at 95°C for 5 min. The
49 equivalent volumes of samples were then loaded onto a 15% SDS-PAGE gel for
50 separation and transferred onto PVDF membranes (Millipore, Sigma). Subsequently,
51 the PVDF membranes were blocked with 1% BSA in TBST for 1hr, followed by
52 overnight incubation with primary antibody, rabbit anti-CD9 (D3H4P; Cell Signaling
53 Technology), mouse anti-CD81 (ab79559; Abcam) and rabbit anti-TSG101
54 (ab125011; Abcam), at 1:2000 ratio in 1% BSA in TBST. After washing, the PVDF
55 membranes were incubated with HRP-conjugated secondary antibody at 1:5000 ratio
56 in 1% BSA in TBST and then scanned by an enhanced chemiluminescence imager
57 (ImageQuant LAS500) for imaging and quantitation.

58 **LC-MS Sample Preparation**

59 EVs isolated from CSF were first lysed in the buffer with 12 mM sodium lauroyl
60 sarcosinate, 12mM sodium deoxycholate, 40 mM CAA, 10 mM TCEP, and
61 phosphatase inhibitor cocktail (Millipore-Sigma) and 50 mM Tris·HCl (pH 8.5)
62 through incubation at 95 °C for 10 min. After five-fold dilution with 50mM
63 triethylammonium bicarbonate (TEAB), the proteins were digested with Lys-C (Wako)
64 with 1:100 w/w ratio for 3 hr at 37°C and subsequently incubated overnight with
65 Trypsin with 1:50 w/w ratio at 37°C. After acidifying the samples by trifluoroacetic
66 acid (TFA) with a final TFA concentration of 1%, ethyl acetate was then added to the
67 samples at 1:1 v/v ratio and the mixed solution was vortexed for 2 min then centrifuged
68 at 15,000 g for 3 min, afterward, the organic phase on the top was removed. Ethyl

69 acetate was added again and above steps were repeated once more. The aqueous phase
70 on the bottom was further dried down in a vacuum freeze centrifuge (Laconco
71 CentriVap) and desalted using an in-house-made C18 Stage-Tip (3M Empore 2240-
72 SDB-XC).

73 For proteome analysis experiment of EVTRAP and UC comparison, whole of each
74 sample was freeze-dried for further LC-MS/MS analysis. While for phosphoproteome
75 analysis of clinical samples, each sample was split into 99 and 1% aliquots for
76 phosphoproteomic and proteomic analysis, respectively, and then dried down and
77 stored at -80°C . The 99% proportion of each sample was used to conduct
78 phosphopeptides enrichment through PolyMAC Phosphopeptides Enrichment Kit
79 (Tymora Analytical) following the manufacturer's instructions and were dried
80 completely after elution.

81 **LC-MS/MS Analysis**

82 Dried peptides and phosphopeptides were dissolved in $10\ \mu\text{L}$ 0.1% formic acid (FA).
83 For proteome analysis of EVTRAP and UC processed samples, $3\ \mu\text{L}$ of each sample was
84 injected into a nanoElute for proteomic analysis. For proteome and phosphoproteome
85 analysis of clinical samples, $2\ \mu\text{L}$ and $7\ \mu\text{L}$ of each was injected, respectively.

86 The mobile phase buffer consisted of 0.1% FA in ultrapure water (buffer A) and in
87 acetonitrile (buffer B). Peptides were separated on a 25cm in-house packed column
88 ($360\ \mu\text{m}$ OD \times $75\ \mu\text{m}$ inner diameter (ID)) containing C18 resin ($1.9\ \mu\text{m}$, 100 Å;
89 Michrom Bioresources) at a flow rate of 300 nL/min with a linear 120 min gradient

90 (2–22% solvent B for 90 min, 22–37% B for 10 min, 37–80% B for 10 min, and 80%
91 B for 10 min) for proteome analysis and a linear 90 min gradient (2–22% solvent B for
92 67.5 min, 22–37% B for 7.5 min, 37–80% B for 7.5 min, and 80% B for 7.5 min) for
93 phosphoproteome analysis.

94 The nanoElute was coupled online with a timsTOF Pro mass spectrometer (Bruker).
95 The mass spectrometer was operated in the data-dependent mode for all the experiments
96 described here, which consists of a full scan MS (from m/z 100 to 1700 with the
97 intensity of 1.5×10^6 at the ‘target value’ resolution of 40,000) along with 10 PASEF
98 MS/MS frames. The quadrupole isolation width was set to 2 Th for $m/z < 700$ and 3 Th
99 for $m/z > 700$. Collision energy was set stepwise changing within a TIMS elution ramp:
100 52 eV for 0–19%, 47 eV for 19–38%, 42 eV for 38–57%, 37 eV for 57–76%, and 32
101 eV for the remainder.

102 **Database Search and Label-free Quantitation Analysis**

103 The raw files were searched directly against the Uniprot database downloaded in
104 November, 2019 with no redundant entries, by PEAKS Studio X+ software
105 (Bioinformatics Solutions Inc.). MS1 precursor mass tolerance was set at 15 ppm
106 initially and the final was set at 6 ppm. MS2 tolerance was set at 0.6 Da. Modification
107 criteria included a static modification of carbamidomethylation on cysteines (+57.0214
108 Da) and variable modifications of acetylation (+42.011 Da) at N terminus of proteins,
109 oxidation (+15.9949 Da) on methionine residues and an extra modification of
110 phosphorylation (+79.996 Da) on serine, threonine, or tyrosine residues for


111 phosphoproteome analysis. Search was performed with semi-specific trypsin/P
112 digestion, allowing a maximum of three missed cleavages on the peptides. The false
113 discovery rates (FDRs) for peptides, proteins, and phosphosites were all set at 1%. All
114 protein and peptide identifications were grouped with no redundant entries. Only
115 unique peptides/phosphopeptides/master proteins were reported.

116 For the quantification of both proteome and phosphoproteome data, the intensities of
117 peptides were extracted with initial precursor mass tolerance of 15 ppm, minimum
118 number of isotope peaks of 2, maximum Δ RT for isotope pattern multiplets -0.2 min,
119 and PSM confidence FDR at 1%. The abundance level of all peptides and proteins was
120 normalized by Total Ion Current (TIC) signals.

121 For differential expression analysis of clinical samples, missing value replacement,
122 normalization, z-score normalization, KW test and heatmap drawing were all carried
123 out using R studio. The significantly changed proteins or phosphopeptides in any
124 sample were identified by the P-value and change fold: P-value ≤ 0.05 , $|\log_2(\text{ratio})| \geq$
125 2.

126


127 **Supplementary Figures**



128

129 **Supplementary Figure S1.** Gene Ontology (GO) analysis of LC-MS proteome data
130 from EV samples captured by EVtrap, using DAVID Bioinformatics Resources (2021
131 Update). (A) Bubble chart of Top10 results for ‘Molecular function’, ‘Biological
132 process’, ‘Cellular Component’ with $-\log_2$ (p-value) and (B) Bar graph of Top10
133 results for ‘Tissue’ with %.


134



135

136 **Supplementary Figure S2.** Repeatability among biological replicates of
 137 phosphoproteome analysis. (A) Venn diagram of identified phosphoproteins (left) and
 138 phosphopeptides (right) in three biological replicates of Control group. (B) Venn
 139 diagram of identified phosphoproteins (left) and phosphopeptides (right) in three
 140 biological replicates of PCNSL group.

141



142

143 **Supplementary Figure S3.** Number of identified peptides and proteins in CSF EV
 144 from PCNSL group and non-PCNSL control, and repeatability among biological
 145 replicates of proteome analysis. (A) Venn diagram of identified proteins (left) and
 146 peptides (right) in three biological replicates of Control group. (B) Venn diagram of
 147 identified proteins (left) and peptides (right) in three biological replicates of PCNSL
 148 group.

149

150 **Supplementary Table S2.** Sample Information.

	PCNSL 1	PCNSL 2	PCNSL 3	Control 1	Control 2	Control 3
Age, mean	63.7	64.3	63.7	50.7	48.7	43
Gender	2F, 1M	2F, 1M	3F	1F, 2M	1F, 2M	1F, 2M

151 M: Male, F: Female.